View Author
cancer prostate prostate cancer study patient biopsy score treatment screening surveillance group value anxiety follow-up outcome diagnosis level gleason result disease european randomized study antigen number european tumour erspc table analysis therapy psa-dt volume urology effect stage progression roobol characteristic prostatectomy questionnaire survival roobol mj psa kinetics randomized cohort management criteria tumor difference max-pc rp group prostate-speci fic antigen favourable parameter knowledge psa level protocol distress tumour volume kinetic pca 3 scale bergh decision mortality prias study hospital schroder selection health rotterdam threshold quality biopsy cores van den bergh university death detection screen-detected measurement chapter
10 Most Recent Publications
|
Timing of Curative Treatment for Prostate Cancer: A Systematic Review
(Article)
Bergh, R.C.N. van den Albertsen, P.C. Bangma, C.H. Freedland, S.J. Graefen, M. Vickers, A.J. Poel, H.G. van der |
2013-02-28
|
|
Sexual function with localized prostate cancer: Active surveillance vs radical therapy
(Article)
Bergh, R.C.N. van den Korfage, I.J. Roobol, M.J. Bangma, C.H. Koning, H.J. de Steyerberg, E.W. Essink-Bot, M.L.E. |
2012-01-20
|
|
Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy
(Article)
Wolters, T. Montironi, R. Kwast, Th.H. van der Mazzucchelli, R. Scarpelli, M. Roobol, M.J. Bergh, R.C.N. van den Leeuwen, P.J. van Hoedemaeker, R.F. Leenders, G.J. van Schröder, F.H. |
2012-01-01
|
|
Re: Delay of surgery in men with low-risk prostate cancer
(Article)
Bergh, R.C.N. van den |
2011-09-01
|
|
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial
(Article)
Wolters, T. Roobol, M.J. Leeuwen, P.J. van Bergh, R.C.N. van den Hoedemaeker, R.F. Leenders, G.J. van Schrder, F.H. Kwast, Th.H. van der |
2011-01-01
|
|
Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: Reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥100)
(Article)
Roobol, M.J. Schröder, F.H. Leenders, G.J. van Hessels, D. Bergh, R.C.N. van den Wolters, T. Leeuwen, P.J. van |
2010-12-01
|
|
Deciding on PSA-screening - Quality of current consumer information on the Internet
(Article)
Korfage, I.J. Bergh, R.C.N. van den Essink-Bot, M.L.E. |
2010-11-01
|
|
Performance of the Prostate Cancer Antigen 3 (PCA3) Gene and Prostate-Specific Antigen in Prescreened Men: Exploring the Value of PCA3 for a First-line Diagnostic Test
(Article)
Roobol, M.J. Schröder, F.H. Leeuwen, P. van Wolters, T. Bergh, R.C.N. van den Leenders, G.J. van Hessels, D. |
2010-10-01
|
|
Journal of Urology: Editorial comment
(Article)
Bergh, R.C.N. van den |
2010-10-01
|
|
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC
(Article)
Wolters, T. Roobol, M.J. Nelen, V. Tammela, T.L. Schröder, F.H. Steyerberg, E.W. Bergh, R.C.N. van den Bangma, C.H. Hugosson, J. Ciatto, S. Kwiatkowski, M. Villers, A. Lujan, M. |
2010-05-15
|
